Conformational specificity of the C4F6 SOD1 antibody; low frequency of reactivity in sporadic ALS cases by Jacob I Ayers et al.
Ayers et al. Acta Neuropathologica Communications 2014, 2:55
http://www.actaneurocomms.org/content/2/1/55RESEARCH Open AccessConformational specificity of the C4F6 SOD1
antibody; low frequency of reactivity in sporadic
ALS cases
Jacob I Ayers1, Guilian Xu1, Olga Pletnikova2, Juan C Troncoso2, P John Hart3,4 and David R Borchelt1*Abstract
Greater than 160 missense mutations in copper-zinc superoxide dismutase-1 (SOD1) can cause amyotrophic lateral
sclerosis (ALS). These mutations produce conformational changes that reveal novel antibody binding epitopes. A
monoclonal antibody, clone C4F6 - raised against the ALS variant G93A of SOD1, has been identified as specifically
recognizing a conformation shared by many ALS mutants of SOD1. Attempts to determine whether non-mutant
SOD1 adopts a C4F6-reactive conformation in spinal tissues of sporadic ALS (sALS) patients has produced inconsistent
results. To define the epitope recognized by C4F6, we tested its binding to a panel of recombinant ALS-SOD1 proteins
expressed in cultured cells, producing data to suggest that the C4F6 epitope minimally contains amino acids 90–93,
which are normally folded into a tight hairpin loop. Multiple van der Waals interactions between the 90–93 loop and a
loop formed by amino acids 37–42, particularly a leucine at position 38, form a stable structure termed the β-plug.
Based on published modeling predictions, we suggest that the binding of C4F6 to multiple ALS mutants of SOD1
occurs when the local structure within the β-plug, including the loop at 90–93, is destabilized. In using the antibody to
stain tissues from transgenic mice or humans, the specificity of the antibody for ALS mutant SOD1 was influenced by
antigen retrieval protocols. Using conditions that showed the best discrimination between normal and misfolded
mutant SOD1 in cell and mouse models, we could find no obvious difference in C4F6 reactivity to spinal motor
neurons between sALS and controls tissues.
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Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disease characterized by the loss of upper and
lower motor neurons. Approximately 90% of the cases
are sporadic (sALS) in origin whereas 10% are familial
(fALS) and caused by mutations identified in more than
10 different genes {http://alsod.iop.kcl.ac.uk/}. One of
the first dominantly-inherited fALS-associated genes to
be identified was the SOD1 gene; mutations in SOD1
account for 10-20% of all fALS cases. There are now
more than 160 missense mutations within this gene that
have been described in ALS patients {http://alsod.iop.kcl.
ac.uk/}. On the basis of studies in various animal* Correspondence: borchelt@mbi.ufl.edu
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unless otherwise stated.models, it is thought that the mutations in SOD1 cause a
gain of toxic properties to produce the progressive para-
lytic symptoms observed in fALS patients. Importantly,
the symptoms and CNS pathology observed in patients
harboring SOD1 mutations are very similar to those ob-
served in non-inherited forms of disease, suggesting that
there could be related mechanisms of pathogenesis.
The toxic properties of mutated SOD1 are thought to
arise from mutation-induced conformational changes
leading to SOD1 misfolding and aggregation. Wild-type
SOD1 (WT) can acquire some of the same properties as
mutant SOD1 when oxidized and stripped of metal
cofactors; these preparations have also been shown to be
toxic when administered to cells [1-5]. Indeed, transgenic
mice that are homozygous for WT SOD1 transgenes and
expressing very high levels of protein form aggregate path-
ology similar to what is seen in mutant SOD1 mice with
paralytic symptoms [6-8]. Additionally, co-expression oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ates the onset of paralysis with evidence that WT SOD1
has been induced to aggregate with mutant SOD1 [9-13].
These studies point to WT SOD1 as a potential patho-
genic link between fALS and sALS and more importantly,
implicate SOD1 as a target for therapeutic intervention in
the majority of ALS cases. Through the course of these
studies, conformation-specific antibodies to SOD1 have
emerged as critical reagents to distinguish misfolded, pre-
sumably toxic SOD1, from protein that achieves a more
native conformation. Examples of these antibodies include
a series of monoclonal antibodies generated by immuniz-
ing mice with a recombinant apo form of G93A hSOD1,
yielding antibodies designated C4F6, A5C3, and D3H5
[14]. To date, however, the epitope recognized by these
antibodies has not been completely characterized.
The anti-hSOD1 antibody, C4F6, which has been widely
used in studies to identify misfolded SOD1, was reported to
show strong immunoreactivity to denatured G93A, signifi-
cant reactivity (but much lower) to other hSOD1 mutants,
and very low reactivity to denatured WT hSOD1 [14]. WT
hSOD1 can be induced to bind C4F6 by oxidation in vitro,
and such reactivity was linked to sporadic ALS by demon-
strating C4F6 immunoreactivity to spinal motor neurons in
sALS cases [5]. However, when Brotherton et al. used C4F6
to stain spinal cord tissue from sALS cases and an A4V
fALS case, they observed that C4F6 reacted with inclusions
in the A4V case but not in the sALS cases [15]. More re-
cently Saxena et al. [16] linked the accumulation of A5C3
reactive mutant SOD1 to motor neuron toxicity in the
G93A mouse model of ALS. With the emergence of these
antibodies as important research tools, and the possible de-
velopment of these antibodies as therapies [17], it is in-
creasingly important to better understand the nature of the
conformational epitope recognized by these antibodies.
The only information currently available on the nature
of the epitope is that it is located in exon 4 of the hSOD1
protein [18], which comprises amino acids 80–119 of
SOD1. We use a combination of immunohistochemical
and biochemical techniques to demonstrate that amino
acids 90–93 of the hSOD1 protein, which comprise a loop
domain between β-strands 5 and 6, are critical compo-
nents of the C4F6 epitope. The key residues identified in
the epitope include an aspartic residue at position 90 that
begins a sequence of Asp-Lys-Asp and position 93 (Ala fa-
vored but Gly tolerated). A comparison of X-ray crystal
structures of WT and G93A SOD1 did not reveal an obvi-
ous conformational change in the 90–93 loop element
that could produce its apparent conformational specificity.
Instead, our data fit best with a model in which any muta-
tion or modification that increases flexibility in the 90–93
loop enables C4F6 reactivity. Furthermore, we systematic-
ally assess the impact of standard antigen retrieval proce-
dures on the immunoreactivity of C4F6, and relatedantibodies, towards mutant and WT SOD1 in fixed tissue
specimens from transgenic mice, finding that standard
antigen retrieval techniques greatly influence reactivity.
Using conditions optimized in the mouse tissues, we
examined the frequency of reactivity with this antibody in
post-mortem spinal cord tissue from 25 sALS cases. In
our hands, none of the sALS cases we examined showed
reactivity that was distinct from what could be observed
in controls.Materials and methods
Transgenic mice
All the strains of transgenic mice used in this study have
been previously described: WT hSOD1 over-expressing
mice used here were the B6SJL-Tg(SOD1)2Gur/J hybrid
line [19], G93A hSOD1 in B6SJL-TgN(SOD1-G93A)1Gur
mice [19], G37R hSOD1 in Gn.G37R Line29 mice [20],
and L126Z hSOD1 in the L126Z Line45 mice [21]. These
mice were all maintained in a hybrid background of
C57BL/6 J and C3H/HeJ. All studies involving mice were
approved by the Institutional Animal Care and Use Com-
mittee at the University of Florida. For identification of
genotype, DNA was extracted from mouse tail biopsies
and analyzed by PCR as previously described [12].Subjects
Tissues from sALS cases were collected with patient
consent and handled under protocols approved by the
Johns Hopkins Institutional Review Board. All samples
were coded and de-identified. Spinal cord tissues from a
total of 25 sALS cases and 5 non-disease controls were
made available for analysis (Additional file 1: Table S1
provides details on the patients and tissues analyzed).
Spinal cord tissues were preserved by immersion fixation
in 10% formalin for at least 14 days and then processed
for paraffin embedding and sectioning at 10 μm. Tissues
from ALS cases were analyzed for the presence of relevant
pathologic features including motor neuron loss, Bunina
body inclusions, Cystatin C positive neuronal inclusions,
skein-like inclusions, and spherical inclusions. For these
pathologies a semi-quantitative assessment of abundance
was used. We also determined which cases showed cor-
pora amylacea inclusions (presence + or absence -).Transgenic mouse tissue collection
Spinal cords were collected from mice for immunohisto-
chemistry (IHC) analysis. Animals were anesthetized
with isoflurane and perfused transcardially with 20 ml of
phosphate-buffered saline followed by 20 ml of 4% para-
formaldehyde. Spinal cords were immediately removed
and placed in 4% paraformaldehyde for 24–48 hours at
4°C prior to paraffin processing.
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To characterize the pathologic features of human sALS
tissues, 10 μm sections were immunostained with ubiquitin
(Rabbit anti-ubiquitin (1:500) from DAKO, CA), which re-
vealed skein-like inclusions, cystatin-C (Rabbit anti-cystatin
C (1:100) from Millipore/Upstate Biotech, Catalog #ABC20.,
Billerica, MA), which revealed Bunina-like inclusions, or by
H&E staining, which revealed Lewy- body-like inclusions
and Bunina body inclusions. All staining of human tissues
used a steam/citrate buffer antigen retrieval protocol. Im-
munohistochemistry on mouse tissues was performed on
5–7 μm sections. Sections were deparaffinized and either
left in water, incubated in 95% formic acid for 20 minutes
followed by overnight incubation in 6 M guanidine hydro-
chloride at room temperature, or steamed in 10 mM citrate
buffer with 0.05% Tween 20, pH 6.0 for 30 minutes.
Sections were blocked of endogenous peroxidases by
immersion in 0.3% H2O2 in PBS following multiple PBS
washes for the sections that underwent antigen re-
trieval. Following blocking of non-specific staining with
10% normal goat serum in PBS containing 0.5% Tween-
20 (PBST), sections were incubated overnight at 4°C
with either the C4F6 antibody (Medimabs, Montreal,
Quebec, Canada) at a 1:500 dilution or the SEDI anti-
body (kind gift from Janice Robertson) at a 1:250 dilu-
tion in PBST with 3% normal goat serum. The sections
were then incubated with a biotinylated secondary anti-
mouse antibody (Vector Laboratories, Burlingame, CA)
diluted 1:500 in PBST with 3% normal goat serum
followed by incubation with the ABC-horseradish per-
oxidase staining kit (Vector Laboratories, Burlingame,
CA). Sections were developed using 0.05% w/v 3,3’-di-
aminobenzidine (Sigma-Aldrich, St. Louis, MO) in PBS
containing 0.0015% H2O2 and counterstained with
hematoxylin. Images were taken using an Olympus
BX60 microscope.
Tissue sections were stained with periodic acid Schiff by
first oxidizing them in 0.5% periodic acid (Fisher Scientific,
Pittsburgh, PA) solution in water for 5 minutes. Following
a rinse in distilled water sections were placed in Schiff ’s
reagent (Sigma-Aldrich, St. Louis, MO) for 15 minutes.
Sections were washed in warm tap water for 5 minutes and
then counterstained in hematoxylin for 1 minute and
washed again in water for 5 minutes. Slides were then
dehydrated and coverslipped.
SOD1 cDNA expression plasmids, cell lines, and
transfections
WTand mutant hSOD1 untagged proteins were expressed
from plasmids based on the mammalian pEF-BOS expres-
sion vector, and have been previously described
[11,22-26]. YFP tagged SOD1 cDNA variants were created
from a worm expression vector (pPD30.38) that contains
WT hSOD1 fused to eYFP (yellow fluorescent protein)kindly provided by Dr. Rick Morimoto (Northwestern
University). Mutant fluorescently tagged SOD1 variants
were constructed following similar procedures and have
been previously described [12,27]. All cDNA genes and
pEF-BOS vectors encoding these cDNAs were verified by
sequencing prior to their use in experimentation. CHO
cells (ATCC, Manassas, VA) were used for all cell culture
studies in which immunocytochemistry (ICC) was to be
performed, and HEK293FT cells (Invitrogen, Carlsbad,
CA) were used if biochemical analysis was to be per-
formed. All cell lines were maintained following ATCC
recommendations.
Transfection of cells for ICC was performed on glass
coverslips that were previously coated with 0.5 mg/ml
poly-L-lysine in 1× phosphate buffered saline solution
(PBS). A total of 0.8 μg of vector DNA was transfected per
well, using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA). For biochemical analyses, a total of 4 μg of vector
DNA was used to transfect cells in 60 mm poly-L-lysine
coated dishes (BD Biosciences, Bedford, MA). Each trans-
fection experiment was repeated a minimum of 3 times.
Immunocytochemistry
After rinsing the cells 3 times in 1× PBS, transfected cells
were fixed with 4% paraformaldehyde in 1× PBS for 15 mi-
nutes. Cells were then permeabilized using ice-cold 100%
methanol for 5 minutes followed by incubation in 20%
normal goat serum in 1× PBS. Immunostaining was then
performed with hSOD1 (1:1000) and C4F6 (1:1000) anti-
bodies in 1× PBS with 10% normal goat serum and incu-
bation overnight at 4°C. Cells were then incubated for
1 hour with secondary antibodies (Invitrogen, Carlsbad,
CA) Alexafluor goat anti-rabbit 568 for hSOD and Alexa-
fluor goat anti-mouse 568 for C4F6 diluted 1:2000 in 1×
PBS with 10% normal goat serum. Cells were treated with
4’,6-diamidino-2-phenylindole, dihydrochloride, stock
14.3 mM (DAPI) (Invitrogen, Carlsbad, CA) diluted
1:2000 in 1× PBS for 10 minutes to visualize nuclei. Fluor-
escence was visualized on an epifluorescence Olympus
BS60 microscope.
Recombinant SOD1 expression and purification
Recombinant hSOD1 proteins were expressed and puri-
fied as previously described [28].
Dot-blot with recombinant SOD1 protein
Recombinant hSOD1 proteins (1.5 μg), as indicated in fig-
ure legends, were spotted onto a nitrocellulose membranes.
The proteins were allowed to dry on the membrane for
30 minutes at 25°C and then the membrane was sub-
merged in PBS for 5 minutes. The membranes were then
incubated in 4% paraformaldehyde for 30 minutes followed
by 5 washes in PBS for 5 minutes each. The membranes
were then treated with varying conditions: 1) submerged in
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merged in 10 mM citrate buffer with 0.05% Tween 20,
pH 6.0 and steamed for 30 minutes. After each treatment
membranes were again washed in PBS 5 times for 5 mi-
nutes each. Odyssey blocking buffer (LI-COR, Lincoln,
NE) was then used to block the membranes for 1 hour. Im-
munostaining was performed by incubating the mem-
branes in a solution of C4F6 (1:1000) and hSOD (1:2500)
antibodies diluted together in Odyssey blocking buffer with
0.1% Tween 20 at 4°C overnight. Membranes were rinsed
in PBST 5 times for 5 minutes each and then incubated in
a solution containing both the IRDye 680RD goat anti-
mouse and IRDye 800CW goat anti-rabbit antibodies
(LI-COR, Lincoln, NE) diluted in Odyssey blocking buffer
containing 0.1% Tween 20 and 0.01% sodium dodecyl sul-
fate for 45 minutes at room temperature. Membranes
were then rinsed 4 times in PBS-T for 5 minutes each, 1
time in PBS for 5 minutes, and then imaged using the
Odyssey Infrared Imaging Systems (LI-COR, Lincoln,
NE). Densitometric analysis was performed using Odyssey
software version 3.0.Immunoblotting
Following transient transfection for 48 hours with
SOD1 constructs as described above, cells were har-
vested in PBS with 1:100 v/v protease inhibitor cock-
tail (Sigma, St. Louis, MO). The cells were then lysed
by sonicating the samples two times for 15 seconds
each before low speed centrifugation (~800 × g) for
10 minutes. Protein concentrations of the supernatant
were then determined by bicinchoninic acid assay as
described by the manufacturer (Pierce Biotechnology,
Rockford, IL). Various protein concentrations, as indi-
cated in figure legends, were boiled for 5 minutes in
Laemmli sample buffer with β-mercaptoethanol and
electrophoresed in 18% Tris-Glycine gels (Invitrogen,
Carlsbad, CA). Following transfer, membranes were
blocked in Odyssey blocking buffer (Odyssey) and subse-
quent processing and imaging using the Odyssey Infra-
red Imaging Systems (LI-COR) was performed as
described for the recombinant dot-blots.Molecular modelling
The conformations (rotamers) adopted by the side chains
of residues E40, D90, K91, D92, and G93 for WT SOD1
were visualized by superimposing 7 structures of 32 sub-
units that are available in the protein data bank (PDB)
(Additional file 2: Table S2) using PyMOL (The PyMOL
Molecular Graphics System, Version 1.7.0, Schrödinger,
LLC). The structural consequences of mutation of G93 to
A was examined in silico by superimposing 3 structures of
16 subunits for G93A SOD1 that are available in the PDB
bank (Additional file 2: Table S2) using PyMOL.Statistical analysis
All statistical analyses were analyzed in GraphPad
PRISM 5.01 Software (la Jolla, CA) as explained in figure
legends.
Results
Characterization of the C4F6 epitope
From previous characterization of the C4F6 antibody, it
had been established that it does not recognize mouse
SOD1 [5]. In the sequences adjacent to the G93A residue,
there is a sequence difference at position 90, which in hu-
man is D and in mouse is G. A mutation of the D at 90 to
alanine causes ALS and has been previously shown to
cause the protein to aggregate [22]. We therefore, tested
the immunoreactivity of C4F6 to the D90A hSOD1 muta-
tion following transient transfection and immunocyto-
chemistry. Robust expression of D90A, along with G93A
and WT SOD1 was indicated by immunostaining with the
control hSOD antibody that can detect all variants of
hSOD1 (Figure 1a-c). However, C4F6 immunoreactivity
was absent in cells transfected with both D90A and the
control WT hSOD1 (Figure 1e,f). As expected G93A
showed strong staining with C4F6 (Figure 1d). This find-
ing indicates that the aspartic acid at amino acid 90 is a
critical component of the C4F6 epitope.
To further demonstrate the importance of this amino
acid, we analyzed immunoblots of cell lysates containing
the WT, G93A, and D90A proteins separated by denatur-
ing SDS-PAGE using the hSOD antibody for assessing
protein loading and the C4F6 antibody to determine rela-
tive affinity (Figure 1). Three different amounts of cell lys-
ate were loaded on the gel. All three hSOD1 proteins
revealed a strong signal when probed with the hSOD anti-
body, with decreasing intensity of reactivity when less pro-
tein was loaded (Figure 1g, asterisk marks position of
primary gene product). The D90A variant exhibits slightly
faster electrophoretic mobility in SDS-PAGE because the
loss of the charged residue increases SDS-binding to the
protein [29]. Using fluorescently-labeled secondary anti-
bodies and the Odyssey Imaging System (see Materials
and methods), the same blot was then probed with the
C4F6 antibody. Although the G93A protein displayed high
immunoreactivity for C4F6, the WT and D90A proteins
were less reactive (Figure 1g). When normalized to the
signal intensity of G93A, the affinity of C4F6 for both the
WT and D90A hSOD1 proteins was 5 or 25-fold lower,
respectively (Figure 1g,h). Together with the immunocyto-
chemical studies, these outcomes provide strong evidence
that the Asp at position 90 is an essential residue in the
epitope for C4F6. Considering also that reactivity for de-
natured G93A SOD1 is much higher than that for dena-
tured WT SOD1, we also conclude that the epitope
extends to position 93. Thus, the minimal epitope for
C4F6 is predicted to be D-K-D-G/A. Importantly, C4F6
Figure 1 The D90A ALS mutant binds C4F6 weakly. Transiently-transfected cells expressing hSOD1 proteins G93A (a, d), WT (b, e), or D90A
(c, f) were immunostained with either hSOD antibody or C4F6 antibody. Nuclei were stained with DAPI (blue). (g) For immunoblot analysis,
HEK293FT cells were transiently transfected with G93A, WT, D90A, or left untransfected (UT) for 48 hours and 50, 10, and 2 μg of total protein
from homogenates were analyzed by SDS-PAGE. (h) Immunoblots similar to those shown in (g) were quantified. At each protein concentration,
the most intense band (asterisk) was quantified and the intensity was normalized to the intensity for the band produced in cells expressing the
G93A variant. The positions of endogenous SOD1 from CHO cells is marked as is the position of an unknown cross-reactive band. In cells
transfected with constructs for G93A SOD1, a second faster migrating band was detected by both hSOD1 and C4F6 antibody (double asterisk).
This band may be a cleavage product of G93A SOD1 or represent protein modified in some manner. Data from 3 replicate experiments were
quantified and graphed (mean ratio ± S.E. (error bars)). Scale bar 50 μm. * P≤ 0.05, *** P≤ 0.001 (unpaired t-test).
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thus could react with SOD1 encoding mutations other
than G93A if the only consequence of the mutation was
to expose the DKDG sequence to allow antibody binding.
Molecular modeling of the C4F6 epitope
To better understand the structure of hSOD1 around
this stretch of amino acids and to determine the struc-
tural consequences of mutations that affect the C4F6epitope, we aligned the crystal structures of 32 subunits
from 7 distinct crystal structures that are in the PDB
database (Additional file 2: Table S2) and merged them
into one molecule to reveal the structural heterogeneity
of our region of interest (Figure 2a). A striking observa-
tion was the high degree of alignment that could be ob-
tained in these structures despite the fact that different
crystallization conditions were used to obtain these data.
Amino acids 90–93 are located in the beta-turn
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of hSOD1 and are in contact with the loop between the
3rd and 4th beta-sheets (Figure 2a). In the WT structure,
the side chain of the lysine at position 91 is highly solvent
exposed and can be found in multiple backbone inde-
pendent rotamers (81 possible; Figure 2a). To determine
how the G93A mutation may alter structure in the 90–93
loop, we performed the same type of structure alignments
for the available structures of the G93A mutant (16 sub-
units from 3 distinct crystal structures; Figure 2b). The
overall architecture of the G93A variant is very similar to
that of WT SOD1, particularly in the loop region of 90–
93 (Figure 2b). Superimposition of the structures of WT
and G93A shows that the overall conformation of the 90–
93 loop, and the adjacent loop between β-strands 3 and 4,
in the G93A variant was not obviously different from that
of WT (Figure 2c and d).
Condition-specific immunoreactivity of C4F6 to hSOD1
variants
To determine the utility of this antibody in tissue prepa-
rations, we tested the immunoreactivity of the antibody
on spinal cord tissue from several lines of transgenic
mice expressing hSOD1 variants following different
antigen retrieval techniques. We compared the C4F6a b
c d
Figure 2 Structure of WT and G93A hSOD1 in the critical C4F6
binding site. (a) The critical amino acids thought to be involved in
C4F6 binding are located in a loop structure formed by amino acids
90–93. (b) Alignment of structures of G93A hSOD1from 3 different
crystals with 16 subunits in the PDB database. (c) Merged alignment
of WT and G93A hSOD1. (d) View of aligned complete structures for
WT and G93A hSOD1.immunoreactivity in 4 different lines of hSOD1 expressing
mice: the Gurney WT line which display no clinical symp-
toms but exhibit some of the vacuolar changes seen in
G93A mutant mice [30], the G93A line of mice that suc-
cumb to disease in 5–7 months of age (in our colony) [19],
the G37R Line 29 mice which develop disease in 7–9
months of age, and the L126Z Line 45 mice that express a
truncated hSOD1 and succumb to disease at 8–10 months
of age. Our forgoing immunoblotting data suggest that de-
naturation of SOD1 protein could reveal the epitope re-
quired for C4F6 immunoreactivity. To test this hypothesis,
we employed a treatment with formic acid to break the
protein crosslinks formed from fixing the tissue with para-
formaldehyde followed by an overnight incubation in 6 M
GdnHCl to denature the protein. Immunoreactivity to the
SEDI antibody that recognizes an epitope buried in the
SOD1 dimer interface was used on the same tissue as a
positive control [31]. This antigen retrieval technique was
observed to greatly increase the reactivity of the SEDI anti-
body, and indicates that this treatment has the potential to
disrupt SOD1 structure and expose buried epitopes
(Additional file 3: Figure S1). In addition to this technique
we also tested the immunoreactivity of C4F6 following
steaming the tissue sections in citrate buffer for 30 minutes,
which is a commonly used antigen retrieval technique. Tis-
sue from hSOD1 non-transgenic mice displayed little or no
immunoreactivity for C4F6 regardless of treatment
(Figure 3a-c). In untreated tissue from mice expressing the
G93A variant of hSOD1, to which the antibody was pro-
duced, strong C4F6 immunoreactivity was observed in the
neuropil, including staining around the vacuolar structures
that are commonly present in this line of mice at endstage
(Figure 3d). The pattern and intensity of reactivity was
changed little by treatment with formic acid and GdnHCl
(Figure 3e). For tissues steamed in citrate buffer, the major
difference observed was increased intra-neuronal staining
in addition to the neuropil reactivity. In untreated tissue
from mice overexpressing WT hSOD1 at ~18 months of
age, rare punctate C4F6 immunoreactivity was observed in
the neuropil and white matter (Figure 3g). Following either
denaturation protocol, C4F6 immunoreactivity greatly in-
creased in the neuropil in addition to staining around the
rim of vacuolar deposits, identical to those found in G93A
tissue from sick mice (Figure 3h,i). Treatment with citrate
buffer seemed to slightly enhance the overall staining when
compared to GdnHCl treatment while also enhancing
neuronal cell body staining.
The evidence that the C4F6 antibody recognizes a
conformational epitope derives from its high reactivity
to fALS mutant SOD1 encoding other disease-associated
mutations; a property that we observe in fixed, but
otherwise untreated, transfected cultured cells [27]. In
our hands, C4F6 staining of spinal cords from paralyzed
G37R mice was relatively weak with only diffuse staining
Figure 3 (a-o) As noted in the margins of the figure, tissue sections from mice overexpressing WT, G93A, G37R, and L126Z hSOD1, or
nontransgenic mice for controls, were stained with C4F6 following either no antigen retrieval, formic acid and 6 M guanidine
hydorchloride (FA & GdnHCL), or steaming in citrate buffer. All tissues from mice expressing mutant hSOD1 (G93A, G37R, and L126Z) were
harvested from paralyzed mice. The WT hSOD1 tissue was from mice ~18 months of age. Arrows in panels d and f highlight staining around the
vacuolar structures commonly present in G93A mice. Scale bar 100 μm.
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bling astrocytes (Figure 3j). In these mice, the overall
level of C4F6 staining was greatly increased following ei-
ther antigen retrieval technique, with increased staining
in neuropil, robust neuronal cell body staining, and
vacuolar staining observed in the gray matter (Figure 3k
and l). Immunoreactivity of C4F6 to spinal cords of par-
alyzed mice expressing the truncated hSOD1 mutant
L126Z was evident, but limited, in untreated tissues, but
appeared to increase in intensity following either antigen
retrieval technique (Figure 3m-o). In these L126Z mice,the antibody appeared to stain intra-cellular fibrillar
structures as well as fibrillar structures in the neuropil.
This model showed very little of the diffuse neuropil
staining that was observed in tissue with the other
SOD1 variants; a finding consistent with previous obser-
vations that this mutation is short-lived and primarily
accumulates only in aggregates [21]. Taken together,
these data reveal that antigen retrieval treatments that
could potentially denature SOD1 produce C4F6 immu-
noreactivity for every SOD1 variant tested, including
over-expressed WT hSOD1.
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niques had on the affinity of C4F6 for the hSOD1 pro-
tein, we spotted purified, recombinant WT, G37R, and
G93A hSOD1 proteins onto nitrocellulose, and fixed
them with paraformaldehyde. The membranes were then
treated with GdnHCl or citrate with steam, before test-
ing immunoreactivity to C4F6. As a control, we also
tested the immunoreactivity of these proteins with the
hSOD antibody. In previous work, we have determined
that this antibody cannot immunoprecipitate natively
folded WT SOD1, but is highly reactive to WT SOD1 in
fixed tissues [32] and to WT SOD1 over-expressed in
cultured cells [27]. Following treatment of the nitrocellu-
lose membrane with 6 M GdnHCl, we found the immu-
noreactivity for both hSOD and C4F6 antibodies was
not significantly altered for any of the hSOD1 proteins
tested (Figure 4a-d). This finding indicates that GdnHCl
alone is not sufficient to denature the protein. Unfortu-
nately, the combination of formic acid with GdnHCl
could not be used because it dissolves nitrocellulose, and
thus we cannot easily assay whether formic acid treat-
ment with GdnHCl efficiently denatures SOD1. When
the membrane was steamed in citrate buffer, the immu-
noreactivity of all three proteins was significantly in-
creased for both hSOD and C4F6 antbodies. ThisFigure 4 Condition-specific immunoreactivity of the hSOD and C4F6
indicated recombinant hSOD1 protein was spotted onto a nitrocellulose m
followed by either no treatment, 6 M guanidine hydrochloride (Para/GdnH
Membranes were then blotted with the hSOD (a) and C4F6 (c) antibodies.
Imaging System with the values normalized to the WT signal, for the hSOD
independent experiments are graphed (mean ratio ± S.E. (error bars)). * P≤finding indicates that the combination of heat and cit-
rate buffer efficiently exposes the epitope for hSOD1
antibody (a peptide antibody) and similarly exposes an
epitope recognized by C4F6.
C4F6 immunoreactivity to misfolded WT SOD1 in
postmortem tissue from sALS cases
As previously discussed, two recent studies have investi-
gated whether WT SOD1 in spinal motor neurons of
sALS cases becomes reactive to the C4F6 antibody, pro-
ducing data that was not entirely comparable because
one study omitted antigen retrieval whereas the other
used citrate/heat treatments [5,15]. Having now achieved
a better understanding of the nature of the epitope and
the effects of antigen retrieval on antibody binding, we
performed C4F6 immunohistochemistry on postmortem
spinal cord tissue from a set of 25 sALS patients and 5
controls. We directly compared the two immunohisto-
chemical protocols: either no antigen retrieval or steam-
ing of the sections in citrate buffer that were used by
Bosco et al. and Brotherton et al. [5,15]. In our hands and
in our patient samples, no significant difference was seen
in the pattern of C4F6 staining whether the tissues were
untreated prior to staining (Additional file 4: Figure S3) or
steamed in citrate (Figure 5). As noted above, citrateantibodies to purified recombinant hSOD1. (a) 1.5 μg of the
embrane. All membranes were treated with 4% paraformaldehyde
Cl), or steamed in citrate buffer (Para/Cit.Buff.) as described in Methods.
(b and d) The intensities of the spots were quantified using an Odyssy
blots, or to the G93A signal, for the C4F6 blots; the data from 3
0.05, *** P≤ 0.001 (unpaired t-test).
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activity to pathologic accumulations of mutant SOD1 in
mice and hence we show images of the citrate treated hu-
man tissues for comparison. As controls for C4F6 stain-
ing, we used murine tissue from non-transgenic or
hSOD1 over-expressing mice (Figure 5a-c). In both sALS
and non-ALS human tissue examined, spherical C4F6-
immunoreactive structures were observed (Figure 5d-f).
These spheroids, which occasionally showed an immuno-
positive ring around a clear center, were found extracellu-
larly throughout the gray and white matter of the spinal
cord sections to varying degrees (Figure 5e-h). Occasion-
ally, we observed extracellular punctate staining in the
gray matter (Figure 5f,g). Eighteen of the 25 sALS cases
and all five of the control cases we examined possessed
these C4F6-reactive spheroids (Additional file 1: Table S1).
Although the majority of cases revealed massive neurode-
generation and motor neuron loss, those tissue sections
that retained motor neurons were devoid of intracellular
C4F6 immunoreactivity. The regular shape of the spheroid
structures was reminiscent of a common feature of adult
human tissues termed corpora amylacea [33]. To deter-
mine the frequency of this pathology in our tissues, we
performed a periodic acid Schiff stain, which is used forFigure 5 Lack of C4F6 immunoreactivity in tissue from sALS cases. Fo
and L126Z (c) hSOD1 overexpressing mice were co-stained. These tissues w
described in Figure 5. (d-f) C4F6 staining of human tissue from non-disease
immunoreactive deposits (3 cases shown). (g, h) Similar structures were ob
control and sALS cases the images shown are from tissues steamed in citra
Figure S3). (i) The spheroid deposits were identical in appearance and freq
arrows) by the Periodic Acid-Schiff stain. Scale bar 100 μm.the detection of these deposits [33]. This stain revealed
that these structures were frequent in our set of cases with
the location and shape of the structure being identical to
the C4F6 immunopositive spheroid deposits. Importantly,
our control cases also had corpora amylacea deposits and
the frequency of these deposits aligned with the frequency
of C4F6 reactive spheroids in our control cases. Therefore,
we concluded that the spheroid inclusion-like reactivity
with C4F6 was either some type of cross reactivity with
the corpora amylacea deposits or some non-disease re-
lated association of SOD1 with these structures. In any
case, the structures were not specific to sALS cases.
Discussion
In this study we sought to more precisely define the epi-
tope of the anti-hSOD1 C4F6 antibody and elucidate the
basis for its ability to specifically recognize many different
ALS mutants of SOD1. Previous studies had determined
that the epitope of C4F6 is located in exon 4 of the
hSOD1 protein, which encompasses amino acids 80 to
119 [5]. Here, we used approaches in immunocytochem-
istry and immunoblotting to demonstrate that residues
90–93 of the protein (DKDG) comprise, at least in part, a
critical element of the epitope recognized by C4F6. Ther a point of reference, tissues from non-transgenic mice (a), WT (b),
ere steamed in citrate buffer to enhance C4F6 immunoreactivity as
controls revealed occasional spheroid (arrow in panel e) and punctate
served in human tissue from sALS cases (2 cases shown). For both the
te. Less staining was observed in untreated tissues (Additional file 4:
uency to structures identified as corpora amylacea (highlighted with
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firmed by demonstrating low immunoreactivity of C4F6
for the D90A variant of hSOD1 (either in fixed cells or on
immunoblots). When C4F6 is presented with denatured
protein on immunoblots, a much higher affinity of the
antibody for SOD1 containing the D-K-D-A sequence at
90–93 (as would be the case for the G93A variant) over
D-A-D-G (for WT hSOD1) was revealed. Thus, our data
strongly implicate amino acids 90 and 93 of the hSOD1
protein as essential elements of the epitope recognized by
C4F6 with residues D at amino acids 90 and G/A at 93
comprising the minimal residues responsible for antibody
binding.
Structurally, amino acids 90–93 are located in the
beta-turn structure formed by the loop between the 5th
and 6th beta strands of hSOD1. An alignment of 32 dis-
tinct WT hSOD1 subunits from the PDB database of 7
independent crystal structures, revealed the consistent
features of the protein’s conformation. The tertiary
structure of WT hSOD1 brings the 90–93 loop in close
proximity to the glutamic acid at position 40, which sits
at the apex of the loop between beta strands 3 and 4.
This region of the protein has been referred to as the β-
plug because L38 caps one end of the β-barrel structure
[34,35]. At the apex of this plug, the side chain of Lys 91
shows two major populations; in one orientation of the
side chain towards Asp 92 and in a less populated orien-
tation toward Glu 40. The later case would favor hydro-
gen bonding between the amino group of Lys 91 and the
carbonyl of the Glu residue at position 40. Additionally,
due to their close proximity, numerous van der Waals
interactions between these two loop structures would
stabilize the native conformation regardless of whether
the side chain of Lys 91 is positioned over Glu 40 or
Asp 92. Collectively, these non-covalent interactions be-
tween the two loops stabilize a tight bend in the back-
bone of the protein to form the loop containing amino
acids 90–93. We propose that in the structure of the
WT native protein, the rigidity of this structure most
likely prevents the C4F6 antibody from binding to an
epitope that consists minimally of residues D-K-D-G/A
at acids 90–93.
The structures available for SOD1-G93A (3 distinct
structures with 16 subunits) show that residues 90–93
are generally found in a similar conformation as ob-
served in WT SOD1. Thus, in comparing the WT and
G93A variants in the region that contains a critical com-
ponent of the epitope there is not an obvious conform-
ational signature that we see as providing specificity for
C4F6 binding. The C4F6 antibody was raised against re-
combinant apo G93A protein, the structure of which
was included in the structures we analyzed and which
completely aligns with that of metallated G93A protein.
Thus, the conformational element caused by the G93Amutation that enables C4F6 binding does not appear to
be due to a stable change in local structure around the
90–93 loop.
In studies of WT and mutant SOD1 expressed in cul-
tured cells, our studies reported here, and previously
[27], indicate that the C4F6 antibody can be used to
detect misfolded mutant SOD1 and that most if not all
fALS mutants share a common misfolded conformation
around the loop between 90–93. By some manner muta-
tions distant from the 90–93 loop, such as A4V [27],
produce a structural change that causes amino acids 90–
93 to adopt a conformation that enables the binding of
C4F6 despite the lack of the favored A at position 93.
NMR studies of the G93A mutant have provided evi-
dence for local changes in protein structure, with the
mutation causing amino acids D90 and V94 to have a
much higher exposure to solvent than exists in the WT
protein [36,37]. Molecular-dynamic simulations of the
A4V, G37R, and H46R variants of SOD1 have suggested
destabilization of the β-plug region, which includes the
90–93 loop [38,39]. Thus, multiple mutations can induce
destabilization of the 90–93 loop and may explain why
C4F6 shows greater reactivity to mutant SOD1 over WT
protein when used for immunocytochemistry on transi-
ently transfected cells [27]. One possible explanation for
the ability of C4F6 to recognize many different mutants
of SOD1 with greater avidity is that many mutations in-
crease mobility in critical elements of the structure and
this increased flexibility is propagated through the back-
bone to reduce the rigidity of the β-plug and allow the
antibody greater access to the weaker epitope of D-K-D-G.
In regard to the conformational specificity of C4F6,
our data indicate that the condition in which we have
the greatest confidence that non-native conformation of
the mutant SOD1 is driving reactivity is when used for
immunocytochemistry in cell models. In our studies of
cells over-expressing human SOD1 encoding ALS muta-
tions other than G93A [27], the antibody consistently
recognizes a subset of cells that over-express mutant
SOD1. In these studies, cells are fixed briefly in parafor-
maldehyde and no particular antigen retrieval is required.
Overall, our experience with the cell models suggests that
C4F6 can discriminate between WT and mutant SOD1 by
immunocytochemistry of fixed cells.
To determine the utility of the antibody in fixed tissues
and the effect of common antigen retrieval procedures on
binding, we examined C4F6 reactivity to spinal cords from
mice overexpressing WT and mutant human SOD1.
Treatments that we assumed would denature SOD1, treat-
ment in formic acid and 6 M GdnHCl or heat treatment
in citrate buffer, resulted in a significant increase in C4F6
staining in spinal cords from all SOD1 variants tested.
Similarly, we observed increased C4F6 reactivity to puri-
fied SOD1 spotted onto nitrocellulose membrane after
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citrate treatment were used, we have confidence that some
of the increased reactivity of the antibody to tissue is due
to direct effects on the protein rather than facilitating bet-
ter access of the antibody to its epitope. Because of the
much greater affinity of the C4F6 antibody for the G93A
protein, we cannot be sure whether the immunoreactivity
detected in these mice is indicative of conformational
change. Notably, in contrast to non-transgenic mice and
mice expressing high levels of WT hSOD1, untreated
spinal cords of paralyzed mice expressing the G37R and
L126Z mutants showed at least some C4F6 immunoreac-
tivity throughout the grey matter; either in the form of
diffuse neuropil reactivity in the G37R mice or as discrete
puncta in the L126Z mice. In all three mutant mouse
models, antigen-retrieval treatments significantly in-
creased the intensity of reactivity and, in the L126Z mice,
elaborated fibrillar inclusions. However, these treatments
also increased reactivity in the WT hSOD1 mice and thus
we attribute C4F6 reactivity in this case to relaxation of
the WT SOD1 structure to loosen the tight bend in the
backbone around amino acids 90–93. Thus, although anti-
gen retrieval methods do appear to enhance C4F6 binding
to accumulations of SOD1 in pathologic structures, indi-
cating the utility of the antibody, users should note that
antigen retrieval methods that could denature SOD1 may
produce C4F6 reactivity that is not necessarily indicative
of the conformational state that existed in living tissue.
The C4F6 monoclonal antibody is one of several that
have been used that were generated by immunizing mice
with human G93A SOD1 [14,40]. To determine whether
our findings for C4F6 may extend to other monoclonal
antibodies of this type, we examined the binding of the
A5C3 monoclonal [40] to cells transfected with vectors
to express WT and the G85R, G93A, and D90A variants
(Additional file 5: Figure S2). Somewhat surprisingly, un-
like C4F6, the A5C3 antibody showed no significant cross
reactivity to G85R hSOD1 (Additional file 5: Figure S2).
This finding suggests that the A5C3 antibody may have a
greater dependency on the presence of an alanine at pos-
ition 93 than the C4F6 antibody.
As described in the Introduction, there have been two
prior studies of whether spinal motor neurons from cases
of sALS show specific immunoreactivity to C4F6 antibody
[5,15]. One of these studies did not use antigen retrieval
(Bosco et al.) while the other used a heat/citrate protocol
similar to what we describe here (Brotherton et al.). In the
Bosco et al. study, they demonstrated that a subset of
motor neurons in a subset of cases (4 of 9) showed aber-
rant C4F6 immunoreactivity of spinal motor neuron cell
bodies [5]. In the Brotherton et al. study, which compared
sALS cases to an A4V fALS case and controls, C4F6 rec-
ognized skein like inclusions (similar to what we observed
in the L126Z mouse model here) in the spinal motorneurons of A4V fALS cases. In sALS cases, as well as con-
trols, no C4F6 reactive inclusions were observed and
instead a more diffuse cell body staining was observed. In
our hands and in our patient samples, whether tissues
were stained without antigen retrieval or after heat/citrate
treatment, the pattern of immunoreactivity in spinal cords
of sALS and control patients were similar. In both, we
observed that the most immunoreactive structures were
extracellular spheroid and punctate deposits. No staining
of motor neuron cell bodies was observed that resembled
the immunoreactive cell bodies identified as containing
misfolded hSOD1 in the Bosco study [5]. We noted a
direct correlation between the frequency of C4F6 reactive
spheroid structures and the frequency of corpora amyla-
cea deposits, which are common glycoproteinacous inclu-
sions that are frequently found in the CNS tissues of
elderly people [33,41]. These structures immunostain for
multiple proteins including ubiquitin, heme oxygenase,
Mn SOD1, and a-synuclein [42]. Whether the SOD1
reactivity present in these structures is indicative of a bio-
logically relevant concentration of the protein or is some
non-specific interaction with other components of the
structure is unknown. The same C4F6 reactive structures
were observed in non-ALS patients and thus these struc-
tures do not represent a disease-specific pathology. Thus,
whether using antigen retrieval, which could reveal patho-
logic accumulations of SOD1, or no antigen retrieval,
which could reveal SOD1 possessing a conformational
signature produced by ALS mutant SOD1, we failed to
detect robust C4F6 reactivity that is specific to sALS
spinal motor neurons. Our data suggest that WT human
SOD1 in spinal motor neurons in post-mortem tissues of
sALS cases is infrequently present in a conformation that
exposes the C4F6 epitope.Additional files
Additional file 1: Table S1. Human Tissue Characteristics.
Additional file 2: Table S2. Details for SOD1 structural analysis.
Additional file 3: Figure S1. Antigen-retrieval impacts SEDI
immunoreactivity to hSOD1 in transgenic mouse spinal cord tissues.
Tissue sections from mice overexpressing WT, G93A, and G37R, or non-
transgenic mice for controls, were stained with SEDI following either no
antigen retrieval or formic acid and 6M guanidine hydrochloride (FA &
GdnHCl). All tissues from mice expressing mutant hSOD1 (G93A and
G37R) were harvested from paralyzed mice. The WT hSOD1 tissue was
from mice ~18 months of age. Scale bar 100 μm.
Additional file 4: Figure S3. C4F6 immunoreactivity in tissue from sALS
cases without antigen retrieval. Tissues from nontransgenic mice (a), WT
(b), and G93A (c) hSOD1 overexpressing mice were stained with C4F6 as
controls. (d) C4F6 staining of human tissue from non-disease controls
revealed very little immunoreactivity. (e, f) In human tissue from sALS
cases (2 cases shown), occasional spheroid deposits appeared to be C4F6
immunopositive. For both the control and sALS cases the images shown
are from tissues not treated for antigen retrieval. The spheroid deposits
were identical in appearance and frequency to structures identified as
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http://www.actaneurocomms.org/content/2/1/55corpora amylacea (highlighted with arrows) by the Periodic Acid-Schiff
stain. Scale bar 200 μm.
Additional file 5: Figure S2. C4F6 and A5C3 differ in their specificity
for SOD1. C4F6 revealed no immunoreactivity to WT SOD1 (c) but
stained cells transfected with G85R SOD1 (d). Following transient
transfection with WT (e, i), G93A (f, j), G85R (g, k), or D90A (h, l) cells
immunostained with the A5C3 antibody only showed reactivity to G93A
(j). Nuclei were stained with DAPI (blue). Scale bar 50 μm.
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